Skip to content

Nutritional Supplementation on Physiological and Metabolic Markers in Females

A Pilot Study Investigating the Effects of a Nutritional Supplement on Physiological and Metabolic Markers in 38-55-year-old Females

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07615777
Enrollment
80
Registered
2026-05-29
Start date
2026-07-09
Completion date
2026-12-01
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Composition Changes, Perimenopausal Women

Keywords

Perimenopause, menopause, metabolism, metabolomics

Brief summary

The goal of this clinical trial is to learn if a 12-week nutritional supplement can result in significant changes in the body composition of 38-55-year-old females. The main questions it aims to answer are: * Does a 12-week nutritional supplementation with myo-inositol, berberine, cinnamon, and chromium lead to significant changes in body composition (e.g. body mass index, body fat composition) in females aged 38-55 compared to placebo? * Does a 12-week nutritional supplementation with myo-inositol, berberine, cinnamon, and chromium lead to significant changes in small molecules (metabolites) in plasma and urine, menopause-related symptoms, and physical performance (e.g. grip strength) in females aged 38-55 compared to placebo? Researchers will compare the nutritional supplement to a placebo (a look-alike substance that contains no nutritional supplement) to see if the intervention works to change body composition in females aged 38-55. Participants will: * Sign a consent form before any procedures begin * Attend two visits to the clinical research facility at Southampton General Hospital over 12 weeks. * Fast before visit's and provide blood and urine samples at each visit * Undergo measurements at each visit, including waist and hip circumferences, grip and leg strength, and body composition. * Complete questionnaires about general health, menopause-related changes, alcohol consumption, physical activity, and diet. * Take 1 capsule 3 times a day at the onset of a meal (once in the morning, once at midday, and once in the evening) for the first 10 days. * Take 3 capsules 3 times a day at the onset of a meal (once in the morning, once at midday, and once in the evening) from day 11 to day 84. * Record supplement intake in a daily compliance diary during the study

Detailed description

Menopause is defined as the reproductive condition of amenorrhea for 12 months, as a result of reduced activity of ovarian follicles and hormonal changes, including oestrogen, androgens, and progesterone. Globally, approximately 47 million females transition into menopause annually. Hormonal decline can reflect in several physical, mental, and genitourinary symptoms. Common physical manifestations include sleep disturbance, hot flushes, mood changes, night sweats, and fatigue. The current average age at menopause in the United Kingdom is 51 years, typically occurring between 45 and 55; however, a significant number of females experience menopause earlier than expected. When menopause occurs before the normal age, it may be classified as premature (before 40 years), early (between 40-45 years), or induced menopause (result of bilateral oophorectomy with or without hysterectomy, removal of the ovaries and fallopian tubes, or ovarian ablation through radiation therapy). Menopause-related physical and metabolic changes are mainly a consequence of oestrogen deficiency, affecting lipid metabolism, insulin resistance, energy consumption, and body fat composition. Changes in body composition during menopause often lead to an increase in body mass index (BMI), particularly due to higher fat accumulation and reduced lean muscle mass. During perimenopause, females experience progressive weight gain at an estimated rate of 1.5 kg per year, resulting in an average increase of approximately 10 kg by the time menopause is reached. Higher BMI during menopause has been linked with an elevated risk of cardiovascular and metabolic diseases. To address these menopause-associated changes, several therapeutic approaches are utilised, including both hormonal and non-hormonal strategies. Natural nutritional supplements have emerged as promising options because of their potential benefits. Among these, cinnamon extracts have gained attention due to their anti-inflammatory, cardiovascular, and immunomodulatory properties, which may alleviate postmenopausal symptoms. Alongside cinnamon, myo-inositol has been shown to alleviate vasomotor symptoms, improving lipid and glucose metabolism and reducing cardiovascular risk factors. By targeting changes in body composition during menopause, nutritional supplements represent a strategic approach to improving quality of life for menopausal females.

Interventions

DIETARY_SUPPLEMENTNutritional Supplement

Nutritional Supplement (myo-inositol, berberine, cinnamon, chromium) composed of 4 natural bioactives extracted from plants, including fruits, roots, barks, and grains.

DIETARY_SUPPLEMENTPlacebo

Placebo: Maltodextrin

Sponsors

University of Southampton
Lead SponsorOTHER
The Better Menopause
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Alphabetically labelled intervention/placebo, with a de-blinding envelope held by an independent researcher at the University of Southampton.

Intervention model description

A n = 80 females (2 treatment arms, each n=40), providing participants with either myo-inositol (2064mg/day), berberine (400mg/day), Cinnasil® (250mg/day) and chromium picolinate (3402mg/day) or placebo.

Eligibility

Sex/Gender
FEMALE
Age
38 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Assigned sex at birth is female * Aged 38-55 years * Experiencing irregular menstrual cycles but not amenorrheic for more than 12 months or have at least one of the following recent symptoms (i.e., from 38 years onwards): (1) hot flushes, (2) sleep disturbances, (3) mood swings, (4) concentration difficulties, (5) bloating or (6) weight gain. * Willing to avoid taking other food supplements during the study period * Able to provide written informed consent

Exclusion criteria

* Diabetes * BMI \<18.5 kg/m2 * Pregnant or trying to get pregnant * No active cancer or cancer within last 5 years * Total Hysterectomy * Known allergies to cinnamon extract, chromium, berberine, myo-inositol * Currently taking part in research, or have done within the last 3 months * Diagnosed autoimmune diseases * Diagnosed hypoglycemia

Design outcomes

Primary

MeasureTime frameDescription
Body mass indexAt the baseline visit and at the end of 12 weeks interventionTo compare the body mass index by measuring the weight after 12-week intervention

Secondary

MeasureTime frameDescription
Body fat compositionAt the baseline visit and at the end of the 12-week interventionTo compare the effect of a 12-week nutritional intervention versus placebo by measuring Waist and hip circumferences
Metabolomic profile of the plasma sampleAt the baseline visit and at the end of 12 weeks interventionTo compare the effect of a 12-week nutritional intervention to a placebo on the plasma metabolome
Metabolomic profile of a urine sampleAt the baseline visit and at the end of 12 weeks interventionTo compare the effect of a 12-week nutritional intervention versus placebo on the urinary metabolome.
Menopause-related changesAt the baseline visit and at the end of 12 weeks interventionTo compare the effect of a 12-week nutritional intervention on self-reported menopause-related changes versus placebo.
Hand grip dynamometryAt the baseline visit and at the end of 12 weeks interventionTo compare the effect of a 12-week nutritional intervention versus placebo on grip strength
Portable strength tracking systemAt the baseline visit and at the end of the 12-week interventionTo compare the effect of a 12-week nutritional intervention versus placebo on leg strength
Transcriptomic profile of blood sampleAt the baseline visit and at the end of the 12-week interventionTo compare the effect of a 12-week nutritional intervention versus placebo on the blood transcriptome

Countries

United Kingdom

Contacts

CONTACTColleen S Deane, PhD
c.s.deane@soton.ac.uk+44 2381208664
CONTACTVeronica F Santiago, PhD
V.F.Santiago@soton.ac.uk+44 2381208664
PRINCIPAL_INVESTIGATORColleen S Deane, PhD

University of Southampton

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026